Anti-HBs response to standard hepatitis B vaccination in children and adolescents with diabetes mellitus

Arslanoglu I., Cetin B., Isguven P., Karavus M.

JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM, cilt.15, sa.4, ss.389-395, 2002 (SCI-Expanded) identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 15 Sayı: 4
  • Basım Tarihi: 2002
  • Dergi Adı: JOURNAL OF PEDIATRIC ENDOCRINOLOGY & METABOLISM
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.389-395
  • Anahtar Kelimeler: hepatitis B, anti-HBs, diabetes mellitus, child, adolescent, vaccine, RECOMBINANT VACCINES, IMMUNE-RESPONSE, PRE-S2 ANTIGEN, YOUNG-PATIENTS, TRANSMISSION, INFECTION, IMMUNOGENICITY, RISK
  • Marmara Üniversitesi Adresli: Evet

Özet

Patients with type 1 diabetes mellitus are expected to respond poorly to hepatitis B (HB) vaccination. In this study we tested this hypothesis for the standard vaccination schedule. Ninety-nine patients (age 10.8 +/- 3.5 years) were vaccinated against HB (10 mug/dose at 0, 1, and 6 months) using a vaccine containing no pre-S-2 antigen (Engerix B*(R)). The sero-conversion and -protection rates after the completion of three doses, the relation of anti-HBs titers to clinical parameters, and comparison with those of healthy counterparts (51 children, aged 9.7 +/- 4.4 years) were analyzed. The vaccine used was pre-S-2 antigen containing (Genhevac B(R)) in 23 and Engerix B(R) in 28; both types yielded a similar response. The geometric mean of the anti-HBs titer was 322.9 vs 1476.8 IU/l (non-significant), sero-convertion rate 96.9% vs 100%, and sero-protection rate 93.9% vs 99% in the diabetic and control groups, respectively. In the diabetic group, there was no correlation between anti-HBs titer and clinical characteristics except for age. We concluded that the standard vaccination schedule is less effective but still effective enough in children and adolescents with type 1 diabetes mellitus.